BRAINSTORM CELL THERAPEUTICS INC.

Brainstorm CELL Therapeutics Inc.

Biotechnology • Healthcare • New York, NY, United States • BCLI (OQB)

Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for treatment of other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Stock Performance (90 Days)

Data through Dec 24, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
PR Newswire • Aug 14
BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
PR Newswire • Nov 14
Brainstorm Cell Therapeutics (BCLI) Price Target Decreased by 13.95% to 17.34 - Nasdaq
Nasdaq • Oct 29
BrainStorm Cell Faces Nasdaq Exit: What the OTCQB Switch Means for Investors and NurOwn Program - Stock Titan
Stock Titan • Jul 17
Halper Sadeh LLC Encourages Brainstorm Cell Therapeutics Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
Business Wire • Oct 27

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has BRAINSTORM CELL THERAPEUTICS INC. had layoffs?
No layoff events have been recorded for BRAINSTORM CELL THERAPEUTICS INC. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does BRAINSTORM CELL THERAPEUTICS INC. have?
BRAINSTORM CELL THERAPEUTICS INC. has approximately 23 employees.
What industry is BRAINSTORM CELL THERAPEUTICS INC. in?
BRAINSTORM CELL THERAPEUTICS INC. operates in the Biotechnology industry, within the Healthcare sector.
Is BRAINSTORM CELL THERAPEUTICS INC. a publicly traded company?
Yes, BRAINSTORM CELL THERAPEUTICS INC. is publicly traded under the ticker symbol BCLI on the OQB. The company has a market capitalization of approximately $0.01 billion.
Where is BRAINSTORM CELL THERAPEUTICS INC. headquartered?
BRAINSTORM CELL THERAPEUTICS INC. is headquartered in New York, NY, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.